1,25-Dihydroxy vitamin D3 treatment attenuates osteopenia, and improves bone muscle quality in Goto-Kakizaki type 2 diabetes model rats

• DOI: 10.1007/s12020-019-01857-5
• Publication Date: 2019-03-02T12:17:30Z
• Authors: Yanlong Liang; Yanzhi Liu; Wenxiu Lai; Minqun Du; Shuhui Li; Limin Zhou; Yulin Mo; Pan Wang; Yalin Min; Liao Cui
• Keywords: Osteopenia; Bone remodeling

Osteopenia and skeletal fragility are considered to be the complications associated with type 2 diabetes mellitus (T2DM). The relationship between glucose metabolism, quality, vitamin D have not been completely understood. We aimed demonstrate a comprehensive bone quality profile in T2DM model subject investigate whether 1, 25-dihydroxy D3 could prevent osteopenia rats. Daily calcitriol (a formulation, 0.045 μg/kg/day) treatment was administered 21-week-old male Goto-Kakizaki (GK) rats genetic non-obese non-insulin-dependent spontaneous rat model) for 20 weeks results were compared those untreated GK rats, wild-type animals. Micro-computed tomography, histomorphometry, mineral density analysis demonstrated that induced significant osteopenia, impairment of microarchitecture biomechanical properties also significantly decreased formation increased resorption parameters three regions skeleton (proximal tibia, mid-shaft lumbar vertebrae), carboxy-terminal I collagen crosslinks, tartrate-resistant acid phosphatase, muscle ubiquitin C, thioredoxin interacting protein (TXNIP) expression. Calcitriol alleviated loss, improved serum glycated levels. Biomarkers increased, while C TXNIP expression following treatment. These suggest 1,25-dihydroxy effectively attenuates improves